UNSPSC 51141549: Beclamide

This classification denotes an anticonvulsant agent with the molecular formula C10H12ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F5N0ALI65V, chemically known as propionamide, n-benzyl-3-chloro- but generally known as beclamide, which bears US NIH Compound Identifier 10391. European Medicines Agency schedules Beclamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05675MIG.

UNSPSC 51141549 Beclamide, a Commodity code, does not reflect the actual scope of work in recent state and local solicitations filed under it. Beclamide is a pharmaceutical compound, but the three recent opportunities posted under this code involve naloxone and drug deactivation systems, therapeutic pharmacy direct-to-manufacturer contracting, and generic multi-source pharmaceuticals with OTC products — a scope substantially broader than a single active pharmaceutical ingredient. State and local health agencies, cooperative purchasing alliances, and public health departments are the primary issuing bodies, with Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) representing the recent activity captured.

The geographic spread spans Florida, Texas, and Minnesota, with MMCAP's footprint extending across multiple states including Oregon. Recent opportunities include Seminole County's IFB60459723LAS (closing July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; Texas HHS's RFI HHS0017013 (posted April 3, 2026) soliciting vendor capability information on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and MMCAP's RFP S1070000015802 (due March 26, 2026) establishing multi-award contracts for generic pharmaceuticals and OTC products across state and local facilities with pricing weighted 75 percent of evaluation. The code shows little relevant recent activity aligned with its nominal commodity definition — the three opportunities are more accurately described as health-system procurement for pharmaceutical services and products rather than procurement of beclamide specifically.